Literature DB >> 6637939

Vasoactive intestinal peptide-secreting tumor appearing as growth failure.

E Granot, R J Deckelbaum, M Schiller, E Okon, K Goder, H Landau, S R Bloom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6637939

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN： 0002-922X


× No keyword cloud information.
  10 in total

1.  Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.

Authors:  Renier Myburgh; Jonathan D Kiefer; Norman F Russkamp; Chiara F Magnani; Nicolás Nuñez; Alexander Simonis; Surema Pfister; C Matthias Wilk; Donal McHugh; Juliane Friemel; Antonia M Müller; Burkhard Becher; Christian Münz; Maries van den Broek; Dario Neri; Markus G Manz
Journal:  Leukemia       Date:  2020-05-01       Impact factor: 11.528

2.  Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.

Authors:  Bin Gu; Bing-Yu Shi; Xiang Zhang; Shi-Yuan Zhou; Jian-Hong Chu; Xiao-Jin Wu; Cheng-Cheng Fu; Hui-Ying Qiu; Yue Han; Su-Ning Chen; Lei Yu; Xiao Ma; De-Pei Wu
Journal:  Bone Marrow Transplant       Date:  2020-06-24       Impact factor: 5.483

3.  Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds.

Authors:  David K Y Zhang; Alexander S Cheung; David J Mooney
Journal:  Nat Protoc       Date:  2020-01-13       Impact factor: 13.491

Review 4.  Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.

Authors:  Juanjuan Zhao; Meirong Wu; Zhifeng Li; Sheng Su; Yin Wen; Litian Zhang; Yuhua Li
Journal:  Ann Hematol       Date:  2020-05-09       Impact factor: 3.673

Review 5.  Development of CAR-T cell therapies for multiple myeloma.

Authors:  Nico Gagelmann; Kristoffer Riecken; Christine Wolschke; Carolina Berger; Francis A Ayuk; Boris Fehse; Nicolaus Kröger
Journal:  Leukemia       Date:  2020-06-22       Impact factor: 11.528

6.  Potential of Chimeric Antigen Receptor T-Cells in Cancer Therapy.

Authors:  Drashti Desai; R S Gaud; Pravin Shende
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  T cell-engaging therapies - BiTEs and beyond.

Authors:  Maria-Elisabeth Goebeler; Ralf C Bargou
Journal:  Nat Rev Clin Oncol       Date:  2020-04-02       Impact factor: 66.675

8.  CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity.

Authors:  Kam Tong Leung; Chi Zhang; Kathy Yuen Yee Chan; Karen Li; John Tak Kit Cheung; Margaret Heung Ling Ng; Xiao-Bing Zhang; Tony Sit; Wayne Yuk Wai Lee; Wei Kang; Ka Fai To; Jasmine Wai Sum Yu; Toni Ki Fong Man; Han Wang; Kam Sze Tsang; Frankie Wai Tsoi Cheng; Grace Kee See Lam; Tin Wai Chow; Alex Wing Kwan Leung; Ting Fan Leung; Patrick Man Pan Yuen; Pak Cheung Ng; Chi Kong Li
Journal:  Leukemia       Date:  2019-10-17       Impact factor: 11.528

Review 9.  Counteracting CAR T cell dysfunction.

Authors:  Mansour Poorebrahim; Jeroen Melief; Yago Pico de Coaña; Stina L Wickström; Angel Cid-Arregui; Rolf Kiessling
Journal:  Oncogene       Date:  2021-01-14       Impact factor: 9.867

10.  Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.

Authors:  Liang Lin; Shih-Feng Cho; Lijie Xing; Kenneth Wen; Yuyin Li; Tengteng Yu; Phillip A Hsieh; Hailin Chen; Metin Kurtoglu; Yi Zhang; C Andrew Stewart; Nikhil Munshi; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Leukemia       Date:  2020-07-06       Impact factor: 11.528
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.